{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:10:06Z","timestamp":1747203006442,"version":"3.40.5"},"reference-count":30,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,15]]},"DOI":"10.20945\/2359-3997000000325","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T19:09:20Z","timestamp":1614193760000},"source":"Crossref","is-referenced-by-count":1,"title":["Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-4576","authenticated-orcid":false,"given":"Fernanda","family":"Bueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5217-3294","authenticated-orcid":false,"given":"Erika","family":"Abelleira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-8459","authenticated-orcid":false,"given":"Florencia","family":"von Stecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-6182","authenticated-orcid":false,"given":"Andrea","family":"Paes de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7085","authenticated-orcid":false,"given":"Fabi\u00e1n","family":"Pitoia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"2","key":"key20210224140918_B1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ecl.2008.02.003","article-title":"Anaplastic thyroid carcinoma","volume":"37","author":"Neff","year":"2008","unstructured":"1. Neff RL, Farrar WB, Kloos RT, Kenneth BD. Anaplastic thyroid carcinoma. Endocrinol Metab Clin North Am. 2008;37(2):525-38.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"key20210224140918_B2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/jso.20691","article-title":"Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies","volume":"94","author":"Green","year":"2006","unstructured":"2. Green LD, Mack L, Pasieka JL. Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. J Surg Oncol. 2006;94(8):725-36.","journal-title":"J Surg Oncol"},{"key":"key20210224140918_B3","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/790834","article-title":"Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer","volume":"2014","author":"Ragazzi","year":"2014","unstructured":"3. Ragazzi M, Ciarrocchi A, Sancisi V, Gandolfi G, Bisagni A, Piana S. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014;2014:790834.","journal-title":"Int J Endocrinol"},{"issue":"9","key":"key20210224140918_B4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1023\/A:1008322002520","article-title":"Anaplastic thyroid carcinoma: current diagnosis and treatment","volume":"11","author":"Giuffrida","year":"2000","unstructured":"4. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment: Ann Oncol. 2000;11(9):1083-9.","journal-title":"Ann Oncol"},{"issue":"6","key":"key20210224140918_B5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2012.0252","article-title":"Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution","volume":"23","author":"Besic","year":"2013","unstructured":"5. Besic N, Gazic B. Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid. 2013;23(6):709-13.","journal-title":"Thyroid"},{"issue":"1","key":"key20210224140918_B6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/ERC-08-0154","article-title":"Anaplastic thyroid carcinoma: molecular pathogenesis and emerging therapies","volume":"16","author":"Smallridge","year":"2009","unstructured":"6. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid carcinoma: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16(1):17-44.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"key20210224140918_B7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","unstructured":"7. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486-97.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"11","key":"key20210224140918_B8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1089\/thy.2014.0004","article-title":"Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012","volume":"24","author":"Brignardello","year":"2014","unstructured":"8. Brignardello E, Palestini N, Felicetti F, Castiglione A, Piovesan A, Gallo M, et al. Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. Thyroid. 2014;24(11): 1600-6.","journal-title":"Thyroid"},{"issue":"12","key":"key20210224140918_B9","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1210\/jc.2017-01180","article-title":"Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer","volume":"102","author":"Prasongsook","year":"2017","unstructured":"9. Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, et al. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017;102(12):4506-14.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20210224140918_B10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/EJE-16-0574","article-title":"Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany","volume":"175","author":"Wendler","year":"2016","unstructured":"10. Wendler J, Kroiss M, Gast K, Kreissl MC, Allelein S, Lichtenauer U, et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol. 2016;175(6):521-9.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"key20210224140918_B11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches","volume":"13","author":"Are","year":"2006","unstructured":"11. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453-64.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"key20210224140918_B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","unstructured":"12. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020;6(9):1-8.","journal-title":"JAMA Oncol"},{"issue":"11","key":"key20210224140918_B13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","unstructured":"13. Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017; 13(11):644-60.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"key20210224140918_B14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.oraloncology.2013.03.440","article-title":"Anaplastic thyroid cancer","volume":"49","author":"O\u2019 Neill","year":"2013","unstructured":"14. O\u2019 Neill JP, Shaha AR. Anaplastic thyroid cancer. Oral Oncol. 2013;49(7):702-6.","journal-title":"Oral Oncol"},{"issue":"11","key":"key20210224140918_B15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid carcinoma","volume":"22","author":"Smallridge","year":"2012","unstructured":"15. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al.; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid carcinoma. Thyroid. 2012;22(11):1104-39.","journal-title":"Thyroid"},{"key":"key20210224140918_B16","doi-asserted-by":"crossref","first-page":"E2083","DOI":"10.1002\/hed.24384","article-title":"Anaplastic thyroid cancer: Prognosis factors, patterns of care, and overall survival","volume":"38","author":"Glaser","year":"2016","unstructured":"16. Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: Prognosis factors, patterns of care, and overall survival. Head Neck. 2016;38:E2083-90. https:\/\/doi.org\/10.1002\/hed.24384.","journal-title":"Head Neck"},{"issue":"8","key":"key20210224140918_B17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2174\/138920211798120808","article-title":"New targeted therapies for thyroid cancer","volume":"12","author":"Antonelli","year":"2011","unstructured":"17. Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, et al. New targeted therapies for thyroid cancer. Curr Genomics. 2011;12(8):626-31.","journal-title":"Curr Genomics"},{"issue":"3","key":"key20210224140918_B18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.21037\/gs.2019.05.05","article-title":"Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up","volume":"8","author":"Antonelli","year":"2019","unstructured":"18. Antonelli A, Ferrari SM, Elia G, Patrizio A, Fallahi P. Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. Gland Surg. 2019;8(3):298-300.","journal-title":"Gland Surg"},{"issue":"11","key":"key20210224140918_B19","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.21073","article-title":"Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations","volume":"103","author":"Quiros","year":"2005","unstructured":"19. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103(11):2261-8.","journal-title":"Cancer"},{"issue":"8","key":"key20210224140918_B20","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","volume":"24","author":"Kunstman","year":"2015","unstructured":"20. Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet. 2015;24(8):2318-29.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"key20210224140918_B21","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly dierentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","unstructured":"21. Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly dierentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052-66.","journal-title":"J Clin Invest"},{"issue":"1","key":"key20210224140918_B22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/thy.2016.0076","article-title":"Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma","volume":"27","author":"Sandulache","year":"2017","unstructured":"22. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, et al. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017;27(1):81-7.","journal-title":"Thyroid"},{"issue":"Suppl 2 (Suppl 2)","key":"key20210224140918_B23","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1186\/1471-2482-13-S2-S44","article-title":"Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review","volume":"13","author":"Guerra","year":"2013","unstructured":"23. Guerra A, Di Crescenzo V, Garzi A, Cinelli M, Carlomagno C, Tonacchera M, et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg 2013; 13 Suppl 2 (Suppl 2):S44.","journal-title":"BMC Surg"},{"issue":"1","key":"key20210224140918_B24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","unstructured":"24. Subbiah V, Cabanillas ME, Kreitman RJ, Wainberg ZA, Cho JY, Keam B, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7-13.","journal-title":"J Clin Oncol"},{"issue":"7","key":"key20210224140918_B25","doi-asserted-by":"crossref","first-page":"e2346","DOI":"10.1210\/clinem\/dgaa246","article-title":"Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy","volume":"105","author":"I\u00f1iguez-Ariza","year":"2020","unstructured":"25. I\u00f1iguez-Ariza NM, Jasim S, Ryder MM, Chintakuntlawar AV, Morris JC, Hilger CR, et al. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. J Clin Endocrinol Metab. 2020;105(7):e2346-57.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20210224140918_B26","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1089\/thy.2020.0251","article-title":"Complete surgical resection after Dabrafenib plus Trametinib treatment in a patient with locally advanced and metastatic anaplastic thyroid carcinoma with a BRAF V600E mutation","volume":"30","author":"Smulever","year":"2020","unstructured":"26. Smulever A, Barrio Lower Daniele S, Damiano G, Pitoia F. Complete surgical resection after Dabrafenib plus Trametinib treatment in a patient with locally advanced and metastatic anaplastic thyroid carcinoma with a BRAF V600E mutation. Thyroid. 2020;30(8):1224-5.","journal-title":"Thyroid"},{"issue":"9","key":"key20210224140918_B27","doi-asserted-by":"crossref","first-page":"e3490","DOI":"10.1210\/clinem\/dgaa421","article-title":"\u201cLetter to the Editor: Foundation One\u2122 Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy\u201d","volume":"105","author":"Pitoia","year":"2020","unstructured":"27. Pitoia F, Smulever A, Jerkovich F. \u201cLetter to the Editor: Foundation One\u2122 Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy\u201d. JCEM. 2020;105(9):e3490-e3491.","journal-title":"JCEM"},{"issue":"9","key":"key20210224140918_B28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","unstructured":"28. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020;383(9):825-35.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20210224140918_B29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","unstructured":"29. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncology. 2020;21(4):531-40.","journal-title":"Lancet Oncology"},{"issue":"8","key":"key20210224140918_B30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E\u2010mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","unstructured":"30. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E\u2010mutated anaplastic thyroid carcinoma. Thyroid. 2019;29(8):1036-43.","journal-title":"Thyroid"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T19:09:44Z","timestamp":1614193784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972021005002203&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":30,"alternative-id":["10.20945\/2359-3997000000325"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000325","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}